Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Melanoma 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Leukemia 2Congenital Abnormalities 2Thymoma 1Sarcoma, Ewing 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Mesothelioma 1Lymphoma, Follicular 1Lymphoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Esophageal Neoplasms 1

Interventions

Cisplatin 11Pemetrexed 10pembrolizumab 9Nivolumab 3LMB-100 3budigalimab 2belinostat 2amatuximab 2Paclitaxel 2Docetaxel 2Dexamethasone 2Cyclophosphamide 2Carboplatin 2Calcium Dobesilate 2venetoclax 1trametinib 1tislelizumab 1tazemetostat 1talazoparib 1spartalizumab 1sodium thiosulfate 1sargramostim 1ruxolitinib 1rovalpituzumab tesirine 1olaparib 1obinutuzumab 1naptumomab estafenatox 1irinotecan sucrosofate 1fludarabine 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Mesothelioma × FANG vaccine × Clear all
NCT01258868 2019-12-03

Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
44 enrolled
GastrointestinalOther solid neoplasmThoracic

Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡